Stocklytics Platform
Asset logo for symbol ONCT
Oncternal Therapeutics
ONCT60
$0.52arrow_drop_down21.06%-$0.14
Penny Stock
Asset logo for symbol ONCT
ONCT60

$0.52

arrow_drop_down21.06%

Performance History

Chart placeholder
Key Stats
Open$0.70
Prev. Close$0.69
EPS-11.69
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.55M
PE Ratio-
LOWHIGH
Day Range0.49
0.70
52 Week Range0.49
13.20
Ratios
Revenue-
EBITDA Margin %-
EPS-11.69

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Oncternal Therapeutics (ONCT)

Oncternal Therapeutics Inc (ONCT) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of cancers. The company is dedicated to the discovery and development of innovative, targeted therapies that address significant unmet medical needs in oncology. With an emphasis on precision medicine, Oncternal Therapeutics is leveraging its extensive experience and expertise in oncology to develop therapies that target specific genetic and molecular pathways involved in the growth and progression of cancer.
The stock price history of Oncternal Therapeutics Inc (ONCT) reflects the company's progress and investor sentiment. Over the past year, the stock has experienced significant fluctuations, with highs and lows reflecting the market's reaction to company news and developments. Investors should carefully consider the risks and potential rewards associated with investing in a clinical-stage biotech company, as there may be a high degree of volatility.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James B. Breitmeyer M.D., Ph.D.
Headquarters
San Diego
Employees
30
Exchange
NASDAQ
add Oncternal Therapeutics  to watchlist

Keep an eye on Oncternal Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Oncternal Therapeutics 's (ONCT) price per share?

The current price per share for Oncternal Therapeutics (ONCT) is $0.53. The stock has seen a price change of -$0.15 recently, indicating a -21.07% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Oncternal Therapeutics (ONCT)?

For Oncternal Therapeutics (ONCT), the 52-week high is $13.2, which is 2.41K% from the current price. The 52-week low is $0.49, the current price is 7.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Oncternal Therapeutics (ONCT) a growth stock?

Oncternal Therapeutics (ONCT) has shown an average price growth of -4.38% over the past three years. It has received a score of 7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Oncternal Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Oncternal Therapeutics (ONCT) stock price performance year to date (YTD)?

As of the latest data, Oncternal Therapeutics (ONCT) has a year-to-date price change of -95.25%. Over the past month, the stock has experienced a price change of -54.6%. Over the last three months, the change has been -63.68%. Over the past six months, the figure is -93.56%. Looking at a longer horizon, the five-year price change stands at -99.41%.
help

Is Oncternal Therapeutics (ONCT) a profitable company?

Oncternal Therapeutics (ONCT) has a net income of -$39.48M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.76K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$41.71M. Furthermore, the EBITDA is $0.
help

What is the market capitalization of Oncternal Therapeutics (ONCT)?

Oncternal Therapeutics (ONCT) has a market capitalization of $1.56M. The average daily trading volume is 0.58, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level